ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/QLD/4215-Southport-Tasman-Oncology
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
13
trial(s) found.
NCT07623369
Advanced
Phase 1
Recruiting
An Open-Label, Multicenter, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Preliminary Antitumor Activity of HH160 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors (
HH160-101
)
trispecific PD-1/VEGFA/CTLA4 antibody
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Endometrial cancer
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Non-small cell lung cancer
Small-cell lung cancer
Solid tumour
Triple-negative breast cancer
Urothelial carcinoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
QLD
4215 - Southport - Tasman Oncology
NCT07545122
Advanced
Phase 1
Recruiting
A Phase 1a/1b, First Time in Human Study of
CT-202
, A Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, and Urothelial Cancers
anti-NECTIN4 antibody-drug conjugate
Colorectal cancer
Triple-negative breast cancer
Urothelial carcinoma
NSW
2076 - Wahroonga - Sydney Adventist Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
QLD
4215 - Southport - Tasman Oncology
WA
6009 - Nedlands - Linear Clinical Research
NCT07238075
Advanced
Phase 1
Recruiting
A First-in-human, Multicenter Dose Escalation and Multiple Cohort Expansion Phase 1a/b Study to Investigate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ADCX-020 in Participants With Locally Advanced or Metastatic Solid Tumors (
ADCX-020-01
)
antibody-drug conjugate,unknown target
Cancer
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
QLD
4215 - Southport - Tasman Oncology
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
SA
5000 - Adelaide - Cancer Research SA
WA
6009 - Nedlands - Linear Clinical Research
NCT07213674
Advanced
Phase 3
Recruiting
A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-na\xEFve Metastatic Castration-resistant Prostate Cancer
CYP17A1 inhibitor
bispecific T-cell engager,STEAP1-targeting
Castrate-resistant prostate cancer
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4215 - Southport - Tasman Oncology
NCT07086105
Advanced
Phase 1
Recruiting
A Phase 1, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Preliminary Efficacy of Intratumoural Adze1.C in Participants With Metastatic Melanoma (
ADZE1.C-001
)
oncolytic virus,CD40L-payload
Melanoma
VIC
3168 - Clayton - Monash Medical Centre
QLD
4215 - Southport - Tasman Oncology
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT07070232
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/II, Open-label, Adaptive Two-part Trial to Evaluate the Safety, Efficacy, Optimal Dose and Pharmacokinetics of BNT326 as Monotherapy and in Combination With Cancer Immunotherapies in Participants With Advanced Solid Tumors (
BNT326-01
)
anti-ERBB3 antibody-drug conjugate
Breast cancer
Cervical cancer
Colorectal adenocarcinoma
Gastroesophageal junction adenocarcinoma
Melanoma
Mucosal melanoma
Non-small cell lung cancer
Solid tumour
Uveal melanoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Cancer Research SA
WA
6009 - Nedlands - One Clinical Research
NCT06764485
Advanced
Phase 3
Recruiting
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) -
rechARge
dual AR degrader antagonist
taxane
Castrate-resistant prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2076 - Wahroonga - Sydney Adventist Hospital
2109 - North Ryde - Macquarie University Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2560 - Campbelltown - GenesisCare Campbelltown
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT06750185
Advanced
Phase 1
Recruiting
A Phase I, First-in-human, Open-label, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BNT317 in Patients With Advanced Solid Tumors (
BNT317-01
)
cancer therapy,undisclosed mechanism
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3168 - Clayton - Monash Medical Centre
QLD
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Cancer Research SA
NCT06623422
Curative
Phase 3
Recruiting
A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009) (
V940-009
)
anti-PD-1 monoclonal antibody
mRNA personalised cancer vaccine
Non-small cell lung cancer
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Tasman Oncology
WA
6009 - Nedlands - One Clinical Research
NZ
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.3210 - Hamilton - Waikato Hospital
NZ.9016 - Dunedin - Dunedin Hospital
NCT06244771
Advanced
Phase 1 / Phase 2
Recruiting
An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants With KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors (
PROSPER
)
KRAS G12C inhibitor,ON/OFF-state inhibitor
Colorectal cancer
Non-small cell lung cancer
Pancreatic cancer
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4215 - Southport - Tasman Oncology
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6009 - Nedlands - Linear Clinical Research
NA
NA
NCT06022029
Haem
Phase 1
Recruiting
A Phase 1 Dose-Escalation and Expansion Study of Intratumorally Administered ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas (
ON-5001
)
STING agonist
anti-PD-1 monoclonal antibody
Bladder cancer
Cancer
Carcinoma
Cervical cancer
Diffuse large B-cell lymphoma
Follicular lymphoma
Head and neck squamous cell carcinoma
Lymphoma
Mantle cell lymphoma
Skin cancer
Triple-negative breast cancer
Uveal melanoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2500 - Wollongong - Cancer Care Wollongong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Tasman Oncology
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT04913285
Advanced
Phase 1
Recruiting
A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants With BRAF and/or NRAS Mutation-positive Solid Tumors. (
KN-8701
)
pan-RAF inhibitor
Melanoma
Non-small cell lung cancer
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4215 - Southport - Tasman Oncology
WA
6009 - Nedlands - Linear Clinical Research
NCT03486873
Advanced
Phase 3
Recruiting
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab (
3475-587
)
anti-PD-1 monoclonal antibody
Haematological malignancy
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2050 - Camperdown - Royal Prince Alfred Hospital - A.W. Morrow Gastroenterology and Liver Centre
2060 - North Sydney - Mater Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4120 - Greenslopes - Greenslopes Private Hospital
4215 - Southport - Gold Coast University Hospital
4215 - Southport - Tasman Oncology
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (13)
Recruitment Country and State
QLD (13)
NSW (12)
WA (9)
VIC (9)
SA (8)
NZ (2)
TAS (1)
Phase
Phase 1 (7)
Phase 1 / Phase 2 (2)
Phase 3 (4)
Trial Type
Advanced (11)
Curative (1)
Haem (1)
Cancer Therapy Class
PD-1/PD-L1
38%
PD-1
31%
VEGFA
15%
CYP17A1
15%
androgen axis
15%
CTLA4
8%
Nectin4
8%
STEAP1
8%
ERBB3
8%
PD-L1
8%
SMO
8%
AR
8%
AR
8%
KRAS
8%
STING
8%
BRAF
8%
CRAF
8%
MEK
8%
RAF
8%
LAG3
8%
PARP
8%
VEGF
8%
Facility
4215 - Southport - Tasman Oncology (13)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (6)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (5)
6009 - Nedlands - Linear Clinical Research (4)
2109 - North Ryde - Macquarie University Hospital (4)
3168 - Clayton - Monash Medical Centre (4)
5000 - Adelaide - Cancer Research SA (3)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (3)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (3)
4102 - Woolloongabba - Princess Alexandra Hospital (3)
2076 - Wahroonga - Sydney Adventist Hospital (2)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (2)
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (2)
5011 - Woodville South - The Queen Elizabeth Hospital (2)
3004 - Melbourne, Southbank - Alfred Health (2)
6009 - Nedlands - One Clinical Research (2)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (2)
3000 - Melbourne - Peter MacCallum Cancer Centre (2)
4120 - Greenslopes - Greenslopes Private Hospital (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (2)
6150 - Murdoch - Fiona Stanley Hospital (2)
NZ.3210 - Hamilton - Waikato Hospital (2)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (2)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
2560 - Campbelltown - GenesisCare Campbelltown (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (1)
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
NA
2500 - Wollongong - Cancer Care Wollongong (1)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (1)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
2050 - Camperdown - Royal Prince Alfred Hospital - A.W. Morrow Gastroenterology and Liver Centre (1)
2060 - North Sydney - Mater Hospital (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
2170 - Liverpool - Liverpool Hospital (1)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
4215 - Southport - Gold Coast University Hospital (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
Cancer Type
Cancer
Solid tumour
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
Urogenital cancer
Breast cancer
Colorectal cancer
Gastrointestinal cancer
Lower gastrointestinal cancer
Melanoma
Breast adenocarcinoma
Cervical cancer
Gynaecological cancer
HPV-related cancer
HPV16-positive cancer
Triple-negative breast cancer
Upper gastrointestinal cancer
Viral-related cancer
Carcinoma
Gastric cancer
Gastric carcinoma
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
Head and neck cancer
Head and neck squamous cell carcinoma
Oesophageal cancer
Urothelial carcinoma
Castrate-resistant prostate cancer
Male genital cancers
Prostate adenocarcinoma
Prostate cancer
Uveal melanoma
Haematological malignancy
Clear cell renal cell carcinoma
Endometrial cancer
Hepatobiliary cancer
Hepatocellular carcinoma
Kidney cancer
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Colorectal adenocarcinoma
Mucosal melanoma
Pancreatic cancer
Pancreatobiliary cancer
B-cell lymphoma
B-cell malignancy
Bladder cancer
Diffuse large B-cell lymphoma
Follicular lymphoma
High-grade B-cell lymphoma
Lymphoma
Mantle cell lymphoma
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Skin cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy